Bio LIMS INC
Mar 17, 2023
BIO LIMS Inc's "AI + Digitalization" strategy is redefining the paradigm of innovative biopharmaceutical R&D and manufacturing.
BIO LIMS Inc's "AI + Digitalization" strategy is redefining the paradigm of innovative biopharmaceutical R&D and manufacturing by combining Large Language Models (LLMs) with Agent technology and integrating them into a comprehensive digital system covering the entire process from research and development to production.
Microservices: The "Hands and Feet" of the System In BIO LIMS Inc's technological architecture, various microservices are built on the Bio-AP technology development platform, encompassing the entire workflow from R&D to production. The solutions we provide include, but are not limited to, Laboratory Information Management System (LIMS), Electronic Lab Notebook (ELN), Manufacturing Execution System (MES), Warehouse Management System (WMS), and data analysis and visualization services. The core advantage of the Bio-AP platform lies in its powerful service assembly capability. Through flexible combination of different microservices, complex business scenario services can be rapidly constructed, such as gene detection, target screening, innovative biopharmaceutical R&D to production, reagent preparation, and full-process information traceability for cell and gene therapy.
LLM+Agent: The Core Engine for Intelligent Decision-Making In BIO LIMS Inc's architecture, LLM plays the role of the "brain," while Agent acts as the "central nervous system" of the intelligent system. LLM provides the foundation for intelligent decision-making with its powerful natural language understanding and generation capabilities. Agent technology, through its planning, reflection, and execution tools, enables seamless connection between LLM and specific microservice functions. These microservice functions, metaphorically described as the system's "hands and feet," can be flexibly registered in the Agent and called upon as needed to execute specific tasks.